STX-100

DB16334Investigational

STX-100 is under investigation in clinical trial NCT01371305 (STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)).

Mechanism: Pharmacologically active on Integrin alpha-V and Integrin beta-6
Curator reviewed
Also known as: Humanized monoclonal antibody against human integrin alphaVbeta6
Code names: STX-100

Resolves to

Compound

Targets

What you can answer from here — as of July 08, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with STX-100, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.